Table 22. [Advantages and Disadvantages of DPP-4 Inhibitors]. - Endotext

Warning: The NCBI web site requires JavaScript to function. more...

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Feingold KR, Anawalt B, Blackman MR, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-.

Endotext [Internet].

Show details

Table 22.

Advantages and Disadvantages of DPP-4 Inhibitors

Advantages	Disadvantages
No hypoglycemia	Pancreatic disease
Weight neutral	Heart failure (saxagliptin/alogliptin)?
Decreases postprandial glucose	Arthritis
Once a day	Bullous pemphigoid
Well tolerated	Relatively expensive
Decreases BP	Modest glycemic lowering

From: Oral and Injectable (Non-Insulin) Pharmacological Agents for the Treatment of Type 2 Diabetes

This electronic version has been made freely available under a Creative Commons (CC-BY-NC-ND) license. A copy of the license can be viewed at http://creativecommons.org/licenses/by-nc-nd/2.0/.

Contents

Views

Cite this Page
Feingold KR. Oral and Injectable (Non-Insulin) Pharmacological Agents for the Treatment of Type 2 Diabetes. [Updated 2024 Sep 11]. In: Feingold KR, Anawalt B, Blackman MR, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-. Table 22. [Advantages and Disadvantages of DPP-4 Inhibitors].

Similar articles in PubMed

Review Complementing insulin therapy to achieve glycemic control.[Adv Ther. 2013]
Review Complementing insulin therapy to achieve glycemic control.
Barnett AH. Adv Ther. 2013 Jun; 30(6):557-76.
Review Potential Role of Phytochemicals as Glucagon-like Peptide 1 Receptor (GLP-1R) Agonists in the Treatment of Diabetes Mellitus.[Pharmaceuticals (Basel). 2024]
Review Potential Role of Phytochemicals as Glucagon-like Peptide 1 Receptor (GLP-1R) Agonists in the Treatment of Diabetes Mellitus.
Abiola JO, Oluyemi AA, Idowu OT, Oyinloye OM, Ubah CS, Owolabi OV, Somade OT, Onikanni SA, Ajiboye BO, Osunsanmi FO, et al. Pharmaceuticals (Basel). 2024 Jun 5; 17(6). Epub 2024 Jun 5.
Real-World Effectiveness of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists (OW GLP-1RAs) in Comparison with Dipeptidyl Peptidase-4 Inhibitors (DPP-4is) for Glycemic Control and Weight Outcomes in Type 2 Diabetes Mellitus (RELATE).[Clin Drug Investig. 2024]
Real-World Effectiveness of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists (OW GLP-1RAs) in Comparison with Dipeptidyl Peptidase-4 Inhibitors (DPP-4is) for Glycemic Control and Weight Outcomes in Type 2 Diabetes Mellitus (RELATE).
Tan X, Divino V, Amamoo J, Xie L, Coyle KB, Gamble CL, Guevarra M, Paprocki Y, King AA. Clin Drug Investig. 2024 Apr; 44(4):271-284. Epub 2024 Mar 20.
Review Choice of Glucose-Lowering Drugs as Initial Monotherapy for Type 2 Diabetes Patients with Contraindications or Intolerance to Metformin: A Systematic Review and Meta-Analysis.[J Clin Med. 2022]
Review Choice of Glucose-Lowering Drugs as Initial Monotherapy for Type 2 Diabetes Patients with Contraindications or Intolerance to Metformin: A Systematic Review and Meta-Analysis.
Gu S, Hu X, Shi L, Zhen X, Sun X, Huang M, Gu Y, Dong H. J Clin Med. 2022 Nov 30; 11(23). Epub 2022 Nov 30.
Review Glycemic control of type 2 diabetes mellitus across stages of renal impairment: information for primary care providers.[Postgrad Med. 2018]
Review Glycemic control of type 2 diabetes mellitus across stages of renal impairment: information for primary care providers.
Tong L, Adler S. Postgrad Med. 2018 May; 130(4):381-393. Epub 2018 Apr 18.

See reviews...See all...

Recent Activity

Clear Turn Off Turn On

Table 22. [Advantages and Disadvantages of DPP-4 Inhibitors]. - Endotext
Table 22. [Advantages and Disadvantages of DPP-4 Inhibitors]. - Endotext

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on